Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Xie, Zhong Xiang ^a   Zhang, Hong Liang ^a,b   Wu, Xiu Juan ^a   Zhu, Jie ^a,b   Ma, Di Hui ^a   Jin, Tao ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYTOKINE; DACLIZUMAB; ESTROGEN; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; LAQUINIMOD; MITOXANTRONE; MONOCLONAL ANTIBODY; MOR 103; NATALIZUMAB; SECUKINUMAB; TERIFLUNOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB; VITAMIN D;

CELL FUNCTION; CENTRAL NERVOUS SYSTEM; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; ANIMAL; ANTIGEN PRESENTING CELL; IMMUNOLOGY;

ANIMALS; ANTIGEN-PRESENTING CELLS; CENTRAL NERVOUS SYSTEM; DENDRITIC CELLS; HUMANS; MULTIPLE SCLEROSIS;

EID: 84937117111     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/513295     Document Type: Review

References (198)

1. J. W. Peterson, L. Bö, S. Mörk, A. Chang, and B. D. Trapp, "Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions, " Annals of Neurology, vol. 50, no. 3, pp. 389-400, 2001.
2. M. Merad, P. Sathe, J. Helft, J. Miller, and A. Mortha, "The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting, " Annual Review of Immunology, vol. 31, pp. 563-604, 2013.
3. D. Vremec, J. Pooley, H. Hochrein, L. Wu, and K. Shortman, "CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen, " Journal of Immunology, vol. 164, no. 6, pp. 2978-2986, 2000.
4. K. Shortman and Y. J. Liu, "Mouse and human dendritic cell subtypes, " Nature Reviews Immunology, vol. 2, no. 3, pp. 151-161, 2002.
5. R. Maldonado-Lopez, T. de Smedt, P. Michelet et al. , "CD8alpha+ and CD8alpha subclasses of dendritic cells direct the development of distinct T helper cells in vivo, " The Journal of Experimental Medicine, vol. 189, no. 3, pp. 587-592, 1999.
6. B. Pulendran, J. L. Smith, G. Caspary et al. , "Distinct dendritic cell subsets differentially regulate the class of immune response in vivo, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 3, pp. 1036-1041, 1999.
7. D. Piccioli, S. Tavarini, E. Borgogni et al. , "Functional specialization of human circulatingCD16 and CD1cmyeloid dendriticcell subsets, " Blood, vol. 109, no. 12, pp. 5371-5379, 2007.
8. L. Ziegler-Heitbrock, "The CD14+ CD16+ blood monocytes: their role in infection and inflammation, " Journal of Leukocyte Biology, vol. 81, no. 3, pp. 584-592, 2007.
9. D. Mittag, A. I. Proietto, T. Loudovaris et al. , "Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status, " Journal of Immunology, vol. 186, no. 11, pp. 6207-6217, 2011.
10. S. L. Jongbloed, A. J. Kassianos, K. J. McDonald et al. , "Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens, " Journal of ExperimentalMedicine, vol. 207, no. 6, pp. 1247-1260, 2010.
11. G. Schreibelt, J. Tel, K. H. E. W. J. Sliepen et al. , "Tolllike receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy, " Cancer Immunology, Immunotherapy, vol. 59, no. 10, pp. 1573-1582, 2010.
12. A. J. Kassianos, M. Y. Hardy, X. Ju et al. , "Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to Escherichia coli, " European Journal of Immunology, vol. 42, no. 6, pp. 1512-1522, 2012.
13. A. Dzionek, A. Fuchs, P. Schmidt et al. , "BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood, " The Journal of Immunology, vol. 165, no. 11, pp. 6037-6046, 2000.
14. F. P. Siegal, N. Kadowaki, M. Shodell et al. , "The nature of the principal type 1 interferon-producing cells in human blood, " Science, vol. 284, no. 5421, pp. 1835-1837, 1999.
15. N. Kadowaki, S. Antonenko, J. Y.-N. Lau, and Y.-J. Liu, "Natural interferon-producing cells link innate and adaptive immunity, " The Journal of Experimental Medicine, vol. 192, no. 2, pp. 219-225, 2000.
16. G. Jego, A. K. Palucka, J. P. Blanck, C. Chalouni, V. Pascual, and J. Banchereau, "Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6, " Immunity, vol. 19, no. 2, pp. 225-234, 2003.
17. N. Schwab, A. L. Zozulya, B. C. Kieseier, K. V. Toyka, and H. Wiendl, "An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation inmultiple sclerosis, " The Journal of Immunology, vol. 184, no. 9, pp. 5368-5374, 2010.
18. M. Mittelbrunn, G. M. Del Hoyo, L.-B. Mara et al. , "Imaging of plasmacytoid dendritic cell interactions with T cells, " Blood, vol. 113, no. 1, pp. 75-84, 2009.
19. H. Ueno, N. Schmitt, E. Klechevsky et al. , "Harnessing human dendritic cell subsets formedicine, " Immunological Reviews, vol. 234, no. 1, pp. 199-212, 2010.
20. W. Chen, X. Liang, A. J. Peterson, D. H. Munn, and B. R. Blazar, "The indoleamine 2, 3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation, " The Journal of Immunology, vol. 181, no. 8, pp. 5396-5404, 2008.
21. T. Ito, M. Yang, Y.-H. Wang et al. , "Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand, "The Journal of ExperimentalMedicine, vol. 204, no. 1, pp. 105-115, 2007.
22. M. Isaksson, B. A. Lundgren, K. M. Ahlgren, O. Kämpe, and A. Lobell, "Conditional DC depletion does not affect priming of encephalitogenic Th cells in EAE, " European Journal of Immunology, vol. 42, no. 10, pp. 2555-2563, 2012.
23. M. B. Lutz, "Therapeutic potential of semi-mature dendritic cells for tolerance induction, " Frontiers in Immunology, vol. 3, article 123, 2012.
24. G. Locafaro, G. Amodio, D. Tomasoni, C. Tresoldi, F. Ciceri, and S. Gregori, "HLA-G expression on blasts and tolerogenic cells in patients affected by acute myeloid leukemia, " Journal of Immunology Research, vol. 2014, no. 10, Article ID636292, 2014.
25. A. E. Morelli and A. W. Thomson, "Tolerogenic dendritic cells and the quest for transplant tolerance, " Nature Reviews Immunology, vol. 7, no. 8, pp. 610-621, 2007.
26. C. A. Colton, "Immune heterogeneity in neuroinflammation: dendritic cells in the brain, " Journal of Neuroimmune Pharmacology, vol. 8, no. 1, pp. 145-162, 2013.
27. G. Brandacher, R. Margreiter, and D. Fuchs, "Clinical relevance of indoleamine 2, 3-dioxygenase for alloimmunity and transplantation, " Current Opinion in Organ Transplantation, vol. 13, no. 1, pp. 10-15, 2008.
28. R. A. Maldonado and U. H. von Andrian, "How tolerogenic dendritic cells induce regulatory T cells, " Advances in Immunology, vol. 108, pp. 111-165, 2010.
29. H. Jonuleit, E. Schmitt, G. Schuler, J. Knop, and A. H. Enk, "Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells, " The Journal of Experimental Medicine, vol. 192, no. 9, pp. 1213-1222, 2000.
30. C. M. U. Hilkens, J. D. Isaacs, and A. W. Thomson, "Development of dendritic cell-based immunotherapy for autoimmunity, " International Reviews of Immunology, vol. 29, no. 2, pp. 156-183, 2010.
31. P. G. McMenamin, "Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations, " Journal of Comparative Neurology, vol. 405, no. 4, pp. 553-562, 1999.
32. J.-M. Serot, M. C. Béné, B. Foliguet, and G. C. Faure, "Monocyte-derived IL-10-secreting dendritic cells in choroid plexus epithelium, " Journal of Neuroimmunology, vol. 105, no. 2, pp. 115-119, 2000.
33. M. Pashenkov, Y.-M. Huang, V. Kostulas, M. Haglund, M. Söderström, and H. Link, "Two subsets of dendritic cells are present in human cerebrospinal fluid, " Brain, vol. 124, no. 3, pp. 480-492, 2001.
34. C. Prodinger, J. Bunse, M. Krüger et al. , "CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system, " Acta Neuropathologica, vol. 121, no. 4, pp. 445-458, 2011.
35. L. Santambrogio, S. L. Belyanskaya, F. R. Fischer et al. , "Developmental plasticity of CNS microglia, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 11, pp. 6295-6300, 2001.
36. H.-G. Fischer and G. Reichmann, "Brain dendritic cells and macrophages/microglia in central nervous system inflammation, " The Journal of Immunology, vol. 166, no. 4, pp. 2717-2726, 2001.
37. D. O. Willenborg and M. A. Staykova, "Cytokines in the pathogenesis and therapy of autoimmune encephalomyelitis and multiple sclerosis, " Advances in ExperimentalMedicine and Biology, vol. 520, pp. 96-119, 2003.
38. L. van de Laar, P. J. Coffer, and A. M. Woltman, "Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy, " Blood, vol. 119, no. 15, pp. 3383-3393, 2012.
39. J. F. Curtin, G. D. King, C. Barcia et al. , "Fins-like tyrosinekinase 3 ligand recruits plasmacytoid dendritic cells to the brain, " Journal of Immunology, vol. 176, no. 6, pp. 3566-3577, 2006.
40. N. Anandasabapathy, G. D. Victora, M. Meredith et al. , "Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain, " The Journal of Experimental Medicine, vol. 208, no. 8, pp. 1695-1705, 2011.
41. X. Zhang and S. Markovic-Plese, "Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis, " Clinical Neurology and Neurosurgery, vol. 112, no. 7, pp. 641-645, 2010.
42. I. Tsunoda and R. S. Fujinami, "Inside-out versus outside-in models for virus induced demyelination: axonal damage triggering demyelination, " Springer Seminars in Immunopathology, vol. 24, no. 2, pp. 105-125, 2002.
43. F. Sato, H. Tanaka, F. Hasanovic, and I. Tsunoda, "Theiler's virus infection: pathophysiology of demyelination and neurodegeneration, " Pathophysiology, vol. 18, no. 1, pp. 31-41, 2011.
44. R. Huizinga, N. Heijmans, P. Schubert et al. , "Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in biozzi ABH mice, " Journal of Neuropathology & Experimental Neurology, vol. 66, no. 4, pp. 295-304, 2007.
45. P. K. Stys, G. W. Zamponi, J. van Minnen, and J. J. G. Geurts, "Will the real multiple sclerosis please stand up?" Nature Reviews Neuroscience, vol. 13, no. 7, pp. 507-514, 2012.
46. D. Ganguly, S. Haak, V. Sisirak, and B. Reizis, "The role of dendritic cells in autoimmunity, " Nature Reviews Immunology, vol. 13, no. 8, pp. 566-577, 2013.
47. S. S. Diebold, "Determination of T-cell fate by dendritic cells, " Immunology and Cell Biology, vol. 86, no. 5, pp. 389-397, 2008.
48. E. M. Frohman, M. K. Racke, and C. S. Raine, "Medical progress: multiple sclerosis-the plaque and its pathogenesis, " The New England Journal of Medicine, vol. 354, no. 9, pp. 942-955, 2006.
49. A. Slavin, L. Kelly-Modis, M. Labadia, K. Ryan, and M. L. Brown, "Pathogenic mechanisms and experimental models of multiple sclerosis, " Autoimmunity, vol. 43, no. 7, pp. 504-513, 2010.
50. M. Greter, F. L. Heppner, M. P. Lemos et al. , "Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis, " Nature Medicine, vol. 11, no. 3, pp. 328-334, 2005.
51. E. J. McMahon, S. L. Bailey, C. V. Castenada, H. Waldner, and S. D. Miller, "Epitope spreading initiates in the CNS in twomouse models of multiple sclerosis, " Nature Medicine, vol. 11, no. 3, pp. 335-339, 2005.
52. M. J. McGeachy, L. A. Stephens, and S. M. Anderton, "Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system, "The Journal of Immunology, vol. 175, no. 5, pp. 3025-3032, 2005.
53. S. Hirata, H. Matsuyoshi, D. Fukuma et al. , "Involvement of regulatory T cells in the experimental autoimmune encephalomyelitis-preventive effect of dendritic cells expressing myelin oligodendrocyte glycoprotein plus TRAIL, " Journal of Immunology, vol. 178, no. 2, pp. 918-925, 2007.
54. N. Yogev, F. Frommer, D. Lukas et al. , "Dendritic cells ameliorate autoimmunity in the cns by controlling the homeostasis of PD-1 receptor+ regulatory T cells, " Immunity, vol. 37, no. 2, pp. 264-275, 2012.
55. S. Takizawa, T. Kaneyama, S. Tsuganeet et al. , "Role of the Programmed Death-1 (PD-1) pathway in regulation ofTheiler's murine encephalomyelitis virus-induced demyelinating disease, " Journal of Neuroimmunology, vol. 274, no. 1-2, pp. 78-85, 2014.
56. S. L. Bailey-Bucktrout, S. C. Caulkins, G. Goings, J. A. A. Fischer, A. Dzionek, and S. D. Miller, "Cutting edge: central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis, " The Journal of Immunology, vol. 180, no. 10, pp. 6457-6461, 2008.
57. M. Irla, N. Küpfer, T. Suter et al. , "MHC class II-restricted antigen presentation by plasmacytoid dendritic cells inhibits T cellmediated autoimmunity, " Journal of ExperimentalMedicine, vol. 207, no. 9, pp. 1891-1905, 2010.
58. Y.-M. Huang, B.-G. Xiao, V. Özenci et al. , "Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines, " Journal of Neuroimmunology, vol. 99, no. 1, pp. 82-90, 1999.
59. M. Pashenkov, N. Teleshova, M. Kouwenhoven et al. , "Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis, " Clinical & Experimental Immunology, vol. 127, no. 3, pp. 519-526, 2002.
60. G. F. Wu and T. M. Laufer, "The role of dendritic cells inmultiple sclerosis, " Current Neurology and Neuroscience Reports, vol. 7, no. 3, pp. 245-252, 2007.
61. A. Karni, M. Abraham, A. Monsonego et al. , "Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response, " Journal of Immunology, vol. 177, no. 6, pp. 4196-4202, 2006.
62. C. López, M. Comabella, H. Al-zayat, M. Tintoré, and X. Montalban, "Altered maturation of circulating dendritic cells in primary progressive MS patients, " Journal of Neuroimmunology, vol. 175, no. 1-2, pp. 183-191, 2006.
63. A. Vaknin-Dembinsky, G. Murugaiyan, D. A. Hafler, A. L. Astier, and H. L. Weiner, "Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis, " Journal of Neuroimmunology, vol. 195, no. 1-2, pp. 140-145, 2008.
64. L. A. Boven, L. Montagne, H. S. L. M. Nottet, and C. J. A. de Groot, "Macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions, " Clinical and Experimental Immunology, vol. 122, no. 2, pp. 257-263, 2000.
65. R. Lande, V. Gafa, B. Serafini et al. , "Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon, " Journal ofNeuropathology and Experimental Neurology, vol. 67, no. 5, pp. 388-401, 2008.
66. A. L. F. Longhini, F. von Glehn, C. O. Brandão et al. , "Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse, " Journal of Neuroinflammation, vol. 8, no. 1, article 2, 2011.
67. M. Stasiolek, A. Bayas, N. Kruse et al. , "Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis, " Brain, vol. 129, no. 5, pp. 1293-1305, 2006.
68. L. L. Aung, P. Fitzgerald-Bocarsly, S. Dhib-Jalbut, and K. Balashov, "Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferonbeta, " Journal ofNeuroimmunology, vol. 226, no. 1-2, pp. 158-164, 2010.
69. J. Navarro, C. Aristimuño, S. Sänchez-Ramón et al. , "Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: differential short-term changes on corticosteroids therapy, " Journal of Neuroimmunology, vol. 176, no. 1-2, pp. 153-161, 2006.
70. M.-S. Krystyna, T. Jacek, R. Sebastian et al. , "Changes in circulating dendritic cells and B-cells in patients with multiple sclerosis relapse during corticosteroid therapy, " Journal of Neuroimmunology, vol. 207, no. 1-2, pp. 107-110, 2009.
71. Y.-M. Huang, N. Stoyanova, Y.-P. Jin et al. , "Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-and IL-10, " Clinical and Experimental Immunology, vol. 124, no. 2, pp. 306-314, 2001.
72. H. C. Heystek, B. den Drijver, M. L. Kapsenberg, R. A. W. van Lier, and E. C. de Jong, "Type I IFNs differentially modulate IL-12p70 production by human dendritic cells depending on the maturation status of the cells and counteract IFN-mediated signaling, " Clinical Immunology, vol. 107, no. 3, pp. 170-177, 2003.
73. X. Zhang, J. Jin, Y. Tang, D. Speer, D. Sujkowska, and S. Markovic-Plese, "IFN-1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 upregulation, " Journal of Immunology, vol. 182, no. 6, pp. 3928-3936, 2009.
74. C. M. Sweeney, R. Lonergan, S. A. Basdeo et al. , "IL-27mediates the response to IFN-therapy in multiple sclerosis patients by inhibitingTh17 cells, " Brain, Behavior, and Immunity, vol. 25, no. 6, pp. 1170-1181, 2011.
75. E. Wiesemann, D. Sönmez, F. Heidenreich, and A. Windhagen, "Interferon-increases the stimulatory capacity of monocytederived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T-cells, " Journal of Neuroimmunology, vol. 123, no. 1-2, pp. 160-169, 2002.
76. B. Schreiner, M. Mitsdoerffer, B. C. Kieseier et al. , "Interferon-enhances monocyte and dendritic cell expression of B7-H1 (PDL1), a strong inhibitor of autologous T-cell activation: relevance for the immunemodulatory effect inmultiple sclerosis, " Journal of Neuroimmunology, vol. 155, no. 1-2, pp. 172-182, 2004.
77. D. S. Kim, K. S. Cho, Y. H. Lee, N. H. Cho, Y. T. Oh, and S. J. Hong, "High-grade hydronephrosis predicts poor outcomes after radical cystectomy in patients with bladder cancer, " Journal of Korean Medical Science, vol. 25, no. 3, pp. 369-373, 2010.
78. M. Chen, G. Chen, S. Deng, X. Liu, G. J. Hutton, and J. Hong, "IFN-induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis, " Journal of Neuroimmunology, vol. 242, no. 1-2, pp. 39-46, 2012.
79. L. L. Aung, A. Brooks, S. A. Greenberg, M. L. Rosenberg, S. Dhib-Jalbut, and K. E. Balashov, "Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells, " Journal of Neuroimmunology, vol. 250, no. 1-2, pp. 99-105, 2012.
80. S. Bakshi, V. Chalifa-Caspi, I. Plaschkes, I. Perevozkin, M. Gurevich, and R. Schwartz, "Gene expression analysis reveals functional pathways of glatiramer acetate activation, " Expert Opinion onTherapeutic Targets, vol. 17, no. 4, pp. 351-362, 2013.
81. Y. Hussien, A. Sanna, M. Söderström, H. Link, and Y.-M. Huang, "Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis, " Journal of Neuroimmunology, vol. 121, no. 1-2, pp. 102-110, 2001.
82. P. L. Vieira, H. C. Heystek, J. Wormmeester, E. A. Wierenga, and M. L. Kapsenberg, "Glatiramer acetate (copolymer-1, copaxone) promotesTh2 cell development and increased IL-10 production through modulation of dendritic cells, " Journal of Immunology, vol. 170, no. 9, pp. 4483-4488, 2003.
83. S. Begum-Haque, M. Christy, Y. Wang et al. , "Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORt responses and by increasing IL-10 production in experimental allergic encephalomyelitis, " Journal of Neuroimmunology, vol. 254, no. 1-2, pp. 117-124, 2013.
84. M. Ruggieri, C. Pica, A. Lia et al. , "Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients, " Journal of Neuroimmunology, vol. 197, no. 2, pp. 140-146, 2008.
85. F. Sellebjerg, D. Hesse, S. Limborg et al. , "Dendritic cell, monocyte and T cell activation and response to glatiramer acetate inmultiple sclerosis, "Multiple Sclerosis, vol. 19, no. 2, pp. 179-187, 2013.
86. K. L. Sand, E. Knudsen, J. Rolin, Y. Al-Falahi, and A. A. Maghazachi, "Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate, " Cellular and Molecular Life Sciences, vol. 66, no. 8, pp. 1446-1456, 2009.
87. M. del Pilar Martin, P. D. Cravens, R. Winger et al. , "Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab, " Archives of Neurology, vol. 65, no. 12, pp. 1596-1603, 2008.
88. C. de Andrés, R. Teijeiro, B. Alonso et al. , "Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis, " PLoS ONE, vol. 7, no. 4, Article ID e34103, 2012.
89. V. Brinkmann, A. Billich, T. Baumruker et al. , "Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis, " Nature Reviews Drug Discovery, vol. 9, no. 11, pp. 883-897, 2010.
90. L. Kappos, E.-W. Radue, P. O'Connor et al. , "A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis, " The New England Journal of Medicine, vol. 362, no. 5, pp. 387-401, 2010.
91. L. Tar and L. Vécsei, "Fingolimod therapy in multiple sclerosis-the issue of the pathomechanism, " Ideggyógyäszati Szemle, vol. 65, no. 3-4, pp. 83-100, 2012.
92. H. Müller, S. Hofer, N. Kaneider et al. , "The immunomodulator FTY720 interferes with effector functions of human monocytederived dendritic cells, " European Journal of Immunology, vol. 35, no. 2, pp. 533-545, 2005.
93. Y. Y. Lan, A. De Creus, B. L. Colvin et al. , "The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking In Vivo, " American Journal of Transplantation, vol. 5, no. 11, pp. 2649-2659, 2005.
94. B. A. Durafourt, C. Lambert, T. A. Johnson, M. Blain, A. Bar-Or, and J. P. Antel, "Differential responses of human microglia and blood-derived myeloid cells to FTY720, " Journal of Neuroimmunology, vol. 230, no. 1-2, pp. 10-16, 2011.
95. T. Vollmer, T. Stewart, and N. Baxter, "Mitoxantrone and cytotoxic drugs' mechanisms of action, " Neurology, vol. 74, supplement 1, pp. S41-S46, 2010.
96. O. Neuhaus, H. Wiendl, B. C. Kieseier et al. , "Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro, " Journal of Neuroimmunology, vol. 168, no. 1-2, pp. 128-137, 2005.
97. J. M. Li, Y. Yang, P. Zhu, F. Zheng, F. L. Gong, and Y. W. Mei, "Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells, " Immunopharmacology and Immunotoxicology, vol. 34, no. 1, pp. 36-41, 2012.
98. A. Aldinucci, T. Biagioli, C. Manuelli, A. M. Repice, L. Massacesi, and C. Ballerini, "Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: A novel mechanism of AZA/6-MP, " Journal of Neuroimmunology, vol. 218, no. 1-2, pp. 28-35, 2010.
99. A. Haghikia and R. Gold, "Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS, " Nature Reviews Neurology, vol. 10, no. 4, pp. 183-184, 2014.
100. A. Sartori, D. Carle, and M. S. Freedman, "Teriflunomide: a novel oral treatment for relapsing multiple sclerosis, " Expert Opinion on Pharmacotherapy, vol. 15, no. 7, pp. 1019-1027, 2014.
101. A. E. Miller, J. S. Wolinsky, L. Kappos et al. , "Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebocontrolled, phase 3 trial, " The Lancet Neurology, vol. 13, no. 10, pp. 977-986, 2014.
102. C. Warnke, G. M. zu Hörste, H.-P. Hartung, O. Stüve, and B. C. Kieseier, "Review of teriflunomide and its potential in the treatment of multiple sclerosis, " Neuropsychiatric Disease and Treatment, vol. 5, no. 1, pp. 333-340, 2009.
103. L. Li, J. Liu, T. Delohery, D. Zhang, C. Arendt, and C. Jones, "The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro, " Journal of Neuroimmunology, vol. 265, no. 1-2, pp. 82-90, 2013.
104. P. Dimitrova, A. Skapenko, M. L. Herrmann, R. Schleyerbach, J. R. Kalden, and H. Schulze-Koops, "Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotesTh2 cell differentiation, " Journal of Immunology, vol. 169, no. 6, pp. 3392-3399, 2002.
105. L. Li, J. Liu, D. Zhang, and C. Jones, "Teriflunomide treatment of human monocyte-derived dendritic cells in vitro does not impair their maturation or ability to induce allogeneic T-cell responses, " Multiple Sclerosis Journal, vol. 18, pp. 436-437, 2012.
106. J. V. Venci andM. A. Gandhi, "Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis, " Annals of Pharmacotherapy, vol. 47, no. 12, pp. 1697-1702, 2013.
107. R. H. Scannevin, S. Chollate, M.-Y. Jung et al. , "Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway, " Journal of Pharmacology and Experimental Therapeutics, vol. 341, no. 1, pp. 274-284, 2012.
108. H. Peng, M. Guerau-de-Arellano, V. B. Mehta et al. , "Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor B (NF-B) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling, "The Journal of Biological Chemistry, vol. 287, no. 33, pp. 28017-28026, 2012.
109. K. Ghoreschi, J. Bruck, C. Kellereret et al. , "Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells, "The Journal of ExperimentalMedicine, vol. 208, no. 11, pp. 2291-2303, 2011.
110. W. Brück and C. Wegner, "Insight into the mechanism of laquinimod action, " Journal of the Neurological Sciences, vol. 306, no. 1-2, pp. 173-179, 2011.
111. V. Jolivel, F. Luessi, J. Masri et al. , "Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis, " Brain, vol. 136, no. 4, pp. 1048-1066, 2013.
112. G. Comi, D. Jeffery, L. Kappos et al. , "Placebo-controlled trial of oral laquinimod for multiple sclerosis, " The New England Journal of Medicine, vol. 366, no. 11, pp. 1000-1009, 2012.
113. M. Filippi, M. A. Rocca, E. Pagani et al. , "Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage, " Journal of Neurology, Neurosurgery & Psychiatry, vol. 85, no. 8, pp. 851-858, 2014.
114. T. L. Vollmer, P. S. Sorensen, K. Selmaj et al. , "A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis, " Journal of Neurology, vol. 261, no. 4, pp. 773-783, 2014.
115. R. Martin, "Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis, " Clinical Immunology, vol. 142, no. 1, pp. 9-14, 2012.
116. R. Gold, G. Giovannoni, K. Selmaj et al. , "Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial, " The Lancet, vol. 381, no. 9884, pp. 2167-2175, 2013.
117. H. Wiendl and C. C. Gross, "Modulation of IL-2R with daclizumab for treatment of multiple sclerosis, " Nature Reviews Neurology, vol. 9, no. 7, pp. 394-404, 2013.
118. K. Mnasria, C. Lagaraine, F. Velge-Roussel, R. Oueslati, Y. Lebranchu, and C. Baron, "Anti-CD25 antibodies affect cytokine synthesis pattern of human dendritic cells and decrease their ability to prime allogeneic CD4+ T cells, " Journal of Leukocyte Biology, vol. 84, no. 2, pp. 460-467, 2008.
119. K. S. Schluns, "Window of opportunity for daclizumab, " Nature Medicine, vol. 17, no. 5, pp. 545-547, 2011.
120. S. C. Wuest, J. H. Edwan, J. F. Martin et al. , "A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy, " Nature Medicine, vol. 17, no. 5, pp. 604-609, 2011.
121. L. Klotz, S. G. Meuth, and H. Wiendl, "Immune mechanisms of new therapeutic strategies in multiple sclerosis-a focus on alemtuzumab, " Clinical Immunology, vol. 142, no. 1, pp. 25-30, 2012.
122. H.-P. Hartung, O. Aktas, and A. N. Boyko, "Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis, " Multiple Sclerosis Journal, 2014.
123. R. A. Diaz, S. Doss, M. J. Burke, E. George, and A. I. Adler, "Alemtuzumab for relapsing-remitting multiple sclerosis, " The Lancet Neurology, vol. 13, no. 9, pp. 869-870, 2014.
124. G. Ratzinger, J. L. Reagan, G. Heller, K. J. Busam, and J. W. Young, "Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation, " Blood, vol. 101, no. 4, pp. 1422-1429, 2003.
125. A. G. S. Buggins, G. J. Mufti, J. Salisbury et al. , "Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab, " Blood, vol. 100, no. 5, pp. 1715-1720, 2002.
126. B. M. Kirsch, M. Haidinger, M. Zeyda et al. , "Alemtuzumab (Campath-1H) induction therapy and dendritic cells: impact on peripheral dendritic cell repertoire in renal allograft recipients, " Transplant Immunology, vol. 16, no. 3-4, pp. 254-257, 2006.
127. E. Havrdovä, A. Belova, A. Goloborodkoet et al. , "Positive proof of concept of AIN457, an antibody against interleukin-17A, in relapsing-remittingmultiple sclerosis, "Multiple Sclerosis Journal, vol. 18, p. 513, 2012.
128. A. Deiß, I. Brecht, A. Haarmann, and M. Buttmann, "Treating multiple sclerosis with monoclonal antibodies: a 2013 update, " Expert Review of Neurotherapeutics, vol. 13, no. 3, pp. 313-335, 2013.
129. J. A. Hamilton, "Colony-stimulating factors in inflammation and autoimmunity, " Nature Reviews Immunology, vol. 8, no. 7, pp. 533-544, 2008.
130. M. Ichikawa, C. S. Koh, A. Inoue et al. , "Anti-IL-12 antibody prevents the development and progression ofmultiple sclerosislike relapsing-remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide, " Journal of Neuroimmunology, vol. 102, no. 1, pp. 56-66, 2000.
131. C. S. Constantinescu, M. Wysocka, B. Hilliardet al. , "Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis, " Journal of Immunology, vol. 161, no. 9, pp. 5097-5104, 1998.
132. H. P. M. Brok, M. van Meurs, E. Blezer et al. , "Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody, " The Journal of Immunology, vol. 169, no. 11, pp. 6554-6563, 2002.
133. B. A. T'Hart, H. P. M. Brok, E. Remarque et al. , "Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody, " The Journal of Immunology, vol. 175, no. 7, pp. 4761-4768, 2005.
134. L. H. Kasper, D. Everitt, T. P. Leistet et al. , "A phase I trial of an interleukin12/23 monoclonal antibody in relapsing multiple sclerosis, " Current Medical Research & Opinion, vol. 22, no. 9, pp. 1671-1678, 2006.
135. B. M. Segal, C. S. Constantinescu, A. Raychaudhuri, L. Kim, R. Fidelus-Gort, and L. H. Kasper, "Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study, " The Lancet Neurology, vol. 7, no. 9, pp. 796-804, 2008.
136. T. L. Vollmer, D. R. Wynn, S. M. Alam, and J. Valdes, "A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and-23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis, " Multiple Sclerosis, vol. 17, no. 2, pp. 181-191, 2011.
137. W. J. Trooster, A. W. Teelken, J. Kampinga, J. G. Loof, P. Nieuwenhuis, and J. M. Minderhoud, "Suppression of acute experimental allergic encephalomyelitis by the synthetic sex hormone 17-alpha-ethinylestradiol: an immunological study in the Lewis rat, " International Archives ofAllergyand Immunology, vol. 102, no. 2, pp. 133-140, 1993.
138. L. Jansson, T. Olsson, and R. Holmdahl, "Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice, " Journal of Neuroimmunology, vol. 53, no. 2, pp. 203-207, 1994.
139. H. Y. Liu, A. C. Buenafe, A. Matejuk et al. , "Estrogen inhibition of EAE involves effects on dendritic cell function, " Journal of Neuroscience Research, vol. 70, no. 2, pp. 238-248, 2002.
140. Q.-H. Zhang, Y.-Z. Hu, J. Cao, Y.-Q. Zhong, Y.-F. Zhao, and Q.-B. Mei, "Estrogen influences the differentiation, maturation and function of dendritic cells in rats with experimental autoimmune encephalomyelitis, " Acta Pharmacologica Sinica, vol. 25, no. 4, pp. 508-513, 2004.
141. A. Pettersson, C. Ciumas, V. Chirsky, H. Link, Y.-M. Huang, and B.-G. Xiao, "Dendritic cells exposed to estrogen in vitro exhibit therapeutic effects in ongoing experimental allergic encephalomyelitis, " Journal of Neuroimmunology, vol. 156, no. 1-2, pp. 58-65, 2004.
142. W.-H. Zhu, C.-Z. Lu, Y.-M. Huang, H. Link, and B.-G. Xiao, "A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2, 3-dioxygenase by dendritic cells, " Multiple Sclerosis, vol. 13, no. 1, pp. 33-40, 2007.
143. S. Du, F. Sandoval, P. Trinh, E. Umeda, and R. Voskuhl, "Estrogen receptor-beta ligand treatment modulates dendritic cells in the target organ during autoimmune demyelinating disease, " European Journal of Immunology, vol. 41, no. 1, pp. 140-150, 2011.
144. S. Simpson Jr. , L. Blizzard, P. Otahal, I. van der Mei, and B. Taylor, "Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis, " Journal of Neurology, Neurosurgery & Psychiatry, vol. 82, no. 10, pp. 1132-1141, 2011.
145. S. Hewer, R. Lucas, I. van derMei, and B. V. Taylor, "Vitamin D and multiple sclerosis, " Journal of Clinical Neuroscience, vol. 20, no. 5, pp. 634-641, 2013.
146. J. Correale, M. C. Ysrraelit, and M. I. Gaitn, "Immunomodulatory effects of Vitamin D in multiple sclerosis, " Brain, vol. 132, no. 5, pp. 1146-1160, 2009.
147. H.-L. Zhang and J. Wu, "Role of vitaminDin immune responses and autoimmune diseases, with emphasis on its role inmultiple sclerosis, " Neuroscience Bulletin, vol. 26, no. 6, pp. 445-454, 2010.
148. L. Piemonti, P. Monti, M. Sironi et al. , "Vitamin D3 affects differentiation, maturation, and function of human monocytederived dendritic cells, " Journal of Immunology, vol. 164, no. 9, pp. 4443-4451, 2000.
149. H. Bartosik-Psujek, J. Tabarkiewicz, K. Pocinska, Z. Stelmasiak, and J. Rolinski, "Immunomodulatory effects of vitamin D on monocyte-derived dendritic cells inmultiple sclerosis, "Multiple Sclerosis, vol. 16, no. 12, pp. 1513-1516, 2010.
150. D. Rach-Regué, L. Grau-López, M. Naranjo-Gómez et al. , "Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients, " European Journal of Immunology, vol. 42, no. 3, pp. 771-782, 2012.
151. A. S. Farias, G. S. Spagnol, P. Bordeaux-Rego et al. , "Vitamin D3 induces IDO+ tolerogenicDCs and enhances Treg, reducing the severity of EAE, " CNSNeuroscience andTherapeutics, vol. 19, no. 4, pp. 269-277, 2013.
152. J. M. Burton, S. Kimball, R. Vieth et al. , "A phase I/II doseescalation trial of vitamin D3 and calcium inmultiple sclerosis, " Neurology, vol. 74, no. 23, pp. 1852-1859, 2010.
153. G. Mosayebi, A. Ghazavi, K. Ghasami, Y. Jand, and P. Kokhaei, "Therapeutic effect of vitamin D3 inmultiple sclerosis patients, " Immunological Investigations, vol. 40, no. 6, pp. 627-639, 2011.
154. R. Kushwah and J. Hu, "Role of dendritic cells in the induction of regulatory T cells, " Cell and Bioscience, vol. 1, no. 1, article 20, 2011.
155. D. M. Mosser and X. Zhang, "Interleukin-10: new perspectives on an old cytokine, " Immunological Reviews, vol. 226, no. 1, pp. 205-218, 2008.
156. S. B. Adikari, A. Petterssor, M. Soderstrom, Y.-M. Huang, and H. Link, "Interleukin-10-modulated immature dendritic cells control the proinflammatory environment in multiple sclerosis, " Scandinavian Journal of Immunology, vol. 59, no. 6, pp. 600-606, 2004.
157. G. Perona-Wright, S. M. Anderton, S. E. M. Howie, and D. Gray, "IL-10 permits transient activation of dendritic cells to tolerize T cells and protect from central nervous system autoimmune disease, " International Immunology, vol. 19, no. 9, pp. 1123-1134, 2007.
158. R. Matsuda, T. Kezuka, C. Nishiyama et al. , "Interleukin-10 gene-transfected mature dendritic cells suppress murine experimental autoimmune optic neuritis, " Investigative Ophthalmology and Visual Science, vol. 53, no. 11, pp. 7235-7245, 2012.
159. S. Gregori, D. Tomasoni, V. Pacciani et al. , "Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway, " Blood, vol. 116, no. 6, pp. 935-944, 2010.
160. G. Amodio and S. Gregori, "Human tolerogenic DC-10: perspectives for clinical applications, " Transplantation Research, vol. 1, no. 1, article 14, 2012.
161. M. Ishikawa, Y. Jin, H. Guo, H. Link, and B.-G. Xiao, "Nasal administration of transforming growth factor-1, induces dendritic cells and inhibits protracted-relapsing experimental allergic encephalomyelitis, " Multiple Sclerosis, vol. 5, no. 3, pp. 184-191, 1999.
162. Y.-X. Jin, L.-Y. Xu, H. Guo, M. Ishikawa, H. Link, and B.-G. Xiao, "TGF-1 inhibits protracted-relapsing experimental autoimmune encephalomyelitis by activating dendritic cells, " Journal of Autoimmunity, vol. 14, no. 3, pp. 213-220, 2000.
163. B. G. Xiao, W. H. Zhu, and C. Z. Lu, "The presence of GMCSF and IL-4 interferes with effect of TGF-beta1 on antigen presenting cells in patients with multiple sclerosis and in rats with experimental autoimmune encephalomyelitis, " Cellular Immunology, vol. 249, no. 1, pp. 30-36, 2007.
164. A. C. Melton, S. L. Bailey-Bucktrout, M. A. Travis, B. T. Fife, J. A. Bluestone, and D. Sheppard, "Expression of v8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice, " The Journal of Clinical Investigation, vol. 120, no. 12, pp. 4436-4444, 2010.
165. M. Acharya, S. Mukhopadhyay, H. Pädassi et al. , "v Integrin expression by DCs is required forTh17 cell differentiation and development of experimental autoimmune encephalomyelitis in mice, " The Journal of Clinical Investigation, vol. 120, no. 12, pp. 4445-4452, 2010.
166. C. L. Langrish, Y. Chen, W. M. Blumenschein et al. , "IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, " The Journal of Experimental Medicine, vol. 201, no. 2, pp. 233-240, 2005.
167. Y. Komiyama, S. Nakae, T. Matsuki et al. , "IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis, " Journal of Immunology, vol. 177, no. 1, pp. 566-573, 2006.
168. H. H. Hofstetter, S. M. Ibrahim, D. Koczan et al. , "Therapeutic efficacy of IL-17 neutralization inmurine experimental autoimmune encephalomyelitis, " Cellular Immunology, vol. 237, no. 2, pp. 123-130, 2005.
169. S. Haak, A. L. Croxford, K. Kreymborg et al. , "IL-17Aand IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice, " Journal of Clinical Investigation, vol. 119, no. 1, pp. 61-69, 2009.
170. B. Becher and B. M. Segal, "T17 cytokines in autoimmune neuro-inflammation, " Current Opinion in Immunology, vol. 23, no. 6, pp. 707-712, 2011.
171. K. Kreymborg, R. Etzensperger, L. Dumoutier et al. , "IL-22 is expressed byTh17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis, " The Journal of Immunology, vol. 179, no. 12, pp. 8098-8104, 2007.
172. J. M. Coquet, S. Chakravarti, M. J. Smyth, and D. I. Godfrey, "Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis, " The Journal of Immunology, vol. 180, no. 11, pp. 7097-7101, 2008.
173. I. Sonderegger, J. Kisielow, R. Meier, C. King, and M. Kopf, "IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo, " European Journal of Immunology, vol. 38, no. 7, pp. 1833-1838, 2008.
174. B. Almolda, M. Costa, M. Montoya, B. Gonzälez, and B. Castellano, "Increase in th17 and t-reg lymphocytes and decrease of il22 correlate with the recovery phase of acute eae in rat, " PLoS ONE, vol. 6, no. 11, Article ID e27473, 2011.
175. W. Xu, R. Y. Li, Y. Dai et al. , "IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis, " Journal of Neuroimmunology, vol. 261, no. 1-2, pp. 87-91, 2013.
176. C. Sutton, C. Brereton, B. Keogh, K. H. G. Mills, and E. C. Lavelle, "A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis, " Journal of Experimental Medicine, vol. 203, no. 7, pp. 1685-1691, 2006.
177. Q. Li, N. Powell, H. Zhang et al. , "Endothelial IL-1R1 is a critical mediator of EAE pathogenesis, " Brain, Behavior, and Immunity, vol. 25, no. 1, pp. 160-167, 2011.
178. B. Cannella and C. S. Raine, "The adhesion molecule and cytokine profile of multiple sclerosis lesions, " Annals of Neurology, vol. 37, no. 4, pp. 424-435, 1995.
179. M. El-Behi, B. Ciric, H. Dai et al. , "The encephalitogenicity of T17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF, " Nature Immunology, vol. 12, no. 6, pp. 568-575, 2011.
180. L. Codarri, G. Gyülvészii, V. Tosevski et al. , "ROR3t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation, " Nature Immunology, vol. 12, no. 6, pp. 560-567, 2011.
181. I. L. King, M. A. Kroenke, and B. M. Segal, "GM-CSFdependent, CD103+ dermal dendritic cells play a critical role inTheffector cell differentiation after subcutaneous immunization, " Journal of ExperimentalMedicine, vol. 207, no. 5, pp. 953-961, 2010.
182. M. Grell, H. Wajant, G. Zimmermann, and P. Scheurich, "The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor, " Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 2, pp. 570-575, 1998.
183. N. H. Ruddle, C. M. Bergman, K. M. McGrath et al. , "An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis, "TheJournal of Experimental Medicine, vol. 172, no. 4, pp. 1193-1200, 1990.
184. G. C. Suvannavejh, H. O. Lee, J. Padilla, M. C. Dal Canto, T. A. Barrett, and S. D. Miller, "Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis ofMOG35-55-induced experimental autoimmune encephalomyelitis, " Cellular Immunology, vol. 205, no. 1, pp. 24-33, 2000.
185. H. Körner, F. A. Lemckert, G. Chaudhri, S. Etteldorf, and J. D. Sedgwick, "Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system, " European Journal of Immunology, vol. 27, no. 8, pp. 1973-1981, 1997.
186. A. Caminero, M. Comabella, and X. Montalban, "Tumor necrosis factor alpha (TNF), anti-TNF-and demyelination revisited: an ongoing story, " Journal of Neuroimmunology, vol. 234, no. 1-2, pp. 1-6, 2011.
187. B. W. Van Oosten, F. Barkhof, L. Truyen et al. , "Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2, " Neurology, vol. 47, no. 6, pp. 1531-1534, 1996.
188. E. B. Samoilova, J. L. Horton, B. Hilliard, T.-S. T. Liu, and Y. Chen, "IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells, " The Journal of Immunology, vol. 161, no. 12, pp. 6480-6486, 1998.
189. S. Serada, M. Fujimoto, M. Mihara et al. , "IL-6 blockade inhibits the induction ofmyelin antigen-specific Th17 cells andTh1 cells in experimental autoimmune encephalomyelitis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 26, pp. 9041-9046, 2008.
190. M. D. Leech, T. A. Barr, D. G. Turner et al. , "Cutting edge: IL-6-Dependent autoimmune disease: dendritic cells as a sufficient, but transient, source, " Journal of Immunology, vol. 190, no. 3, pp. 881-885, 2013.
191. D. Maimone, G. C. Guazzi, and P. Annunziata, "IL-6 detection in multiple sclerosis brain, " Journal of the Neurological Sciences, vol. 146, no. 1, pp. 59-65, 1997.
192. B. C. Kieseier, O. Stüve, T. Dehmel et al. , "Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses, " JAMA Neurology, vol. 70, no. 3, pp. 390-393, 2013.
193. M. Menges, S. Rößner, C. Voigtländer et al. , "Repetitive injections of dendritic cells matured with tumor necrosis factor induce antigen-specific protection of mice fromautoimmunity, " The Journal of Experimental Medicine, vol. 195, no. 1, pp. 15-21, 2002.
194. S. Hirata, S. Senju, H. Matsuyoshi, D. Fukuma, Y. Uemura, and Y. Nishimura, "Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand 1, " Journal of Immunology, vol. 174, no. 4, pp. 1888-1897, 2005.
195. R. Thomé, L. K. Issayama, R. Digangi et al. , "Dendritic cells treated with chloroquine modulate experimental autoimmune encephalomyelitis, " Immunology and Cell Biology, vol. 92, no. 2, pp. 124-132, 2014.
196. F. Zhou, B. Ciric, G.-X. Zhang, and A. Rostami, "Immunotherapy using lipopolysaccharide-stimulated bone marrowderived dendritic cells to treat experimental autoimmune encephalomyelitis, " Clinical & Experimental Immunology, vol. 178, no. 3, pp. 447-458, 2014.
197. F. Zhou, E. Lauretti, A. di Meco et al. , "Intravenous transfer of apoptotic cell-treated dendritic cells leads to immune tolerance by blocking Th17 cell activity, " Immunobiology, vol. 218, no. 8, pp. 1069-1076, 2013.
198. M. Isaksson, B. Ardesjö, L. Rönnblom et al. , "Plasmacytoid DC promote priming of autoimmuneTh17 cells and EAE, " European Journal of Immunology, vol. 39, no. 10, pp. 2925-2935, 2009.